Star Tv Canlı Sefirin Kızı, Gesundheit Ist Das Höchste Gut, Neuer Konzertsaal München Standort, Laura Berlin Größe, Vertrauen Sprüche Zum Nachdenken, Last Day Game, La Spezia Hotel, Lesen Und Schreiben Lernen, Dunclair Dunkin Donuts, " />

pieris investor relations

Box 30170 College Station, TX 77842-3170 T: 1- 877-373-6374 (US, Canada, Puerto Rico)1-781-575-3100 (non-US) web.queries@computershare.com www.computershare.com/investor. Investor Relations (781) 292-4279 info@verastem.com. Investor Relations Contact: Pieris Pharmaceuticals, Inc. Maria Kelman : Director of Investor Relations +1 857 362 9635 kelman@pieris.com : SOURCE: Pieris Pharmaceuticals, Inc. You can learn more about our use of cookies and similar technologies and your choices by reviewing our Cookies Policy. Argot Partners (617) 340-6075 joseph@argotpartners.com corporate info. BOSTON, MA / ACCESSWIRE / October 28, 2020 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer and other indications, today announced that it will host a third quarter 2020 investor call on Wednesday, November 4, 2020 at 8:00 AM EST to discuss financial results and provide a corporate update. Director of Investor Relations +1 857 362 9635. Pieris Pharmaceuticals, Inc. is a, clinical-stage biotechnology company committing to providing novel solutions for oncology, respiratory disease and other therapeutic areas by applying its proprietary Anticalin® technology to create differentiated drugs. investor relations - reports. Our pipeline includes inhalable Anticalin proteins to treat respiratory diseases and immuno-oncology multi-specifics tailored for the tumor microenvironment. Pieris is a clinical-stage biotechnology company that discovers and develops Anticalin protein-based drugs to target validated disease pathways in a unique and transformative way. Transfer Agent Computershare P.O. investor relations. Pieris Pharmaceuticals, Inc. The following slide deck was published by Pieris Pharmaceuticals, Inc. in … Investor Contact. SOURCE: Pieris Pharmaceuticals, Inc. The use of this website is governed by the Terms of Use. The Investor Relations website contains information about Syndax Pharmaceuticals, Inc.'s business for stockholders, potential investors, and financial analysts. financial reporting. Investor Relations. Investor Relations Contact: Pieris Pharmaceuticals, Inc. ... Director of Investor Relations +1 857 362 9635. kelman@pieris.com. Investor Relations Contact: Pieris Pharmaceuticals, Inc. ... Director of Investor Relations +1 857 362 9635. kelman@pieris.com. investor relations. An archived replay of the call will be available for 30 days by dialing 877-660-6853 (Toll Free US & Canada) or 201-612-7415 (International) and providing the Conference ID #13661472. American Stock Transfer & Trust Company, LLC Attn. From philanthropic efforts to advocacy initiatives, we are living our values throughout our communities. T: 281-589-5200 IR@callon.com. useful links. Investors should consult all of the information set forth herein and should also refer to the risk factor disclosure set forth in the reports and other documents we file with the SEC available at www.sec.gov, including without limitation the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2019 and the Company's Quarterly Reports on Form 10-Q. More than 150 years of quality, integrity and service. Pieris Pharmaceuticals, Inc.Maria KelmanDirector of Investor Relations+1 857 362 9635kelman@pieris.com. John Doyle. Proprietary to Pieris, Anticalin proteins are a novel class of therapeutics validated in the clinic and by partnerships with leading pharmaceutical companies. Statements in this press release that are not purely historical are forward-looking statements. Pieris will host an investor conference call on Thursday, January 5, 2017 at 8:30 AM (EST) to discuss the collaboration. financial reporting. Pieris Pharmaceuticals, Inc. today announced that it will host a second quarter 2020 investor call on Monday, August 10, 2020 at 8:00 AM EDT to discuss financial results and provide a corporate update. You can learn more about our use of cookies and similar technologies and your choices by reviewing our Cookies Policy. Use of cookies on this website: This website uses cookies to give you the best user experience, for analytics, and improvement of functionalities of this website and third party sites. Investor Relations Contact: Pieris Pharmaceuticals, Inc. Maria Kelman Director of Investor Relations +1 857 362 9635 kelman@pieris.com. Pieris Pharmaceuticals to Host Third Quarter... https://www.accesswire.com/612696/Pieris-Pharmaceuticals-to-Host-Third-Quarter-2020-Investor-Call-and-Corporate-Update-on-November-4-2020. Our libraries of more than 100 billion different Anticalin proteins can virtually bind to any target of interest, Corporate Address: Investor Relations Contact: Pieris Pharmaceuticals, Inc. Maria Kelman Director of Investor Relations +1 857 362 9635 kelman@pieris.com. Pieris Pharmaceuticals (PIRS) Investor Presentation - Slideshow. By using this website you acknowledge that you have read the Privacy Policy and Terms of Use and the disclaimers and caveats contained therein and you accept and agree to be bound by the terms thereof. To access the call, participants may dial 1-877-407-8920 (US & Canada) or 1-412-902-1010 (International) at least 10 minutes prior to the start of the call. Investor Relations Institutional Ownership and Shareholders Pieris Pharmaceuticals, Inc. (US:PIRS) has 201 institutional owners and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). Contact Investor Relations . Our Culture. By clicking "I agree" you agree to our use of cookies. Investor Relations Contact: Pieris Pharmaceuticals, Inc. Maria Kelman Director of Investor Relations +1 857 362 9635 kelman@pieris.com. BOSTON, MA / ACCESSWIRE / May 4, 2020 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer and other indications, today announced that it will host a first quarter 2020 investor call on Monday, May 11, 2020 at 8:00 … Plains All American Pipeline (NYSE: PAA) Plains All American Pipeline is a publicly traded master limited partnership (“MLP”). For more information, visit www.pieris.com. Investor Relations Contact: Pieris Pharmaceuticals, Inc. Maria Kelman Director of Investor Relations +1 857 362 9635 kelman@pieris.com. In 2017, Pieris forged strategic alliances with Servier and AstraZeneca to accelerate its transformation into a fully-integrated, biologics R&D and commercial organization, focused on two immunology-related therapeutic areas: immuno-oncology and respiratory disease. Anticalin proteins are recombinantly engineered versions of lipocalins, human proteins that naturally bind, store and transport a wide spectrum of molecules. Joe Rayne. Investor Relations. 9th floor Boston, MA 02109, Investor Relations BOSTON, MA / ACCESSWIRE / October 28, 2020 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer and other indications, today announced that it will host a third quarter 2020 investor call on Wednesday, November 4, … PIERIS PHARMACEUTICALS, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited, in thousands) The foundation of Pieris' partnerships and R&D efforts is a proprietary class of clinically-tested next generation therapeutics, Anticalin proteins. Such forward-looking statements include, among other things, the timing for, and outcome of, the additional in-use and compatibility study for PRS-343 as requested by the FDA; whether data from patients enrolled to date will be sufficient to inform the recommended phase 2 dose for the Company's planned proof of concept study of PRS-343 in gastric cancer; the expected timing and potential outcomes of the reporting by the Company of key clinical data from its programs, references to novel technologies and methods and our business and product development plans, including the advancement of our proprietary and co-development programs into and through the clinic and the expected timing for reporting data, making IND filings or achieving other milestones related to our programs, including PRS-060/AZD1402, PRS-343, PRS-344, and PRS-352 and the expected timing of the initiation of the next stage of PRS-343's development in gastric cancer.

Star Tv Canlı Sefirin Kızı, Gesundheit Ist Das Höchste Gut, Neuer Konzertsaal München Standort, Laura Berlin Größe, Vertrauen Sprüche Zum Nachdenken, Last Day Game, La Spezia Hotel, Lesen Und Schreiben Lernen, Dunclair Dunkin Donuts,